Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
2239000
Reference Type
Journal Article
Title
Clevidipine in the treatment of perioperative hypertension: assessing safety events in the ECLIPSE trials
Author(s)
Aronson, S
Year
2009
Is Peer Reviewed?
Yes
Journal
Expert Review of Cardiovascular Therapy
ISSN:
1477-9072
Volume
7
Issue
5
Page Numbers
465-472
Language
English
PMID
19419254
DOI
10.1586/erc.09.1
Abstract
Clevidipine is an arterial, selective, dihydropyridine calcium channel blocker with an ultrashort half-life. In this prospective, randomized, open-label, parallel-comparison trial series, the safety and efficacy of intravenous clevidipine with nitroglycerin, sodium nitroprusside and nicardipine in hypertensive patients during cardiac surgery were compared. No differences in the incidences of myocardial infarction, stroke or renal dysfunction were observed between treatment groups. Mortality was similar between the clevidipine-nitrogylcerine- and clevidipine-nicardipine-treated groups, whereas mortality appeared to be greater in the sodium nitroprusside group compared to clevidipine (p = 0.04 in a univariant analysis). Clevidipine was significantly more effective in blood pressure control compared with nitroglycerin (p = 0.0006) or sodium nitroprusside (p = 0.003) and was associated with fewer blood pressure excursions compared with nicardipine as a predetermined blood pressure range was narrowed.
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity